Overview
Autosomal dominant popliteal pterygium syndrome (PPS), also known as facio-genito-popliteal syndrome, is a rare congenital disorder characterized by a combination of orofacial, musculoskeletal, and genitourinary anomalies. It is caused by mutations in the IRF6 gene, the same gene implicated in Van der Woude syndrome, and is inherited in an autosomal dominant pattern with variable expressivity. PPS is allelic to Van der Woude syndrome but generally presents with a broader and more severe spectrum of features. The hallmark feature of popliteal pterygium syndrome is the presence of webbing (pterygia) behind the knees (popliteal fossae), which can restrict leg movement and range from mild skin folds to extensive webs containing muscles, nerves, and blood vessels. Other key clinical features include cleft lip and/or cleft palate, lip pits (small depressions on the lower lip), syndactyly (webbing of fingers or toes), and genital anomalies such as cryptorchidism or scrotal malformations in males and labial hypoplasia in females. Additional findings may include ankyloblepharon filiforme adnatum (thin bands of tissue connecting the upper and lower eyelids), oral synechiae (bands connecting the upper and lower jaws), hypoplastic nails, and a distinctive pyramidal fold of skin over the hallux toenail. Treatment of popliteal pterygium syndrome is symptomatic and multidisciplinary. Surgical intervention is typically required to release popliteal webbing and improve mobility, repair cleft lip and palate, and address genital anomalies. Careful surgical planning is essential because the popliteal pterygia may contain the sciatic nerve or popliteal vessels. Orthopedic, plastic surgical, and urological specialists are often involved in the management of affected individuals. Genetic counseling is recommended for affected families given the autosomal dominant inheritance pattern and the 50% recurrence risk for offspring of affected individuals.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Autosomal dominant popliteal pterygium syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Autosomal dominant popliteal pterygium syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Autosomal dominant popliteal pterygium syndrome.
Community
No community posts yet. Be the first to share your experience with Autosomal dominant popliteal pterygium syndrome.
Start the conversation →Latest news about Autosomal dominant popliteal pterygium syndrome
No recent news articles for Autosomal dominant popliteal pterygium syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Autosomal dominant popliteal pterygium syndrome
What is Autosomal dominant popliteal pterygium syndrome?
Autosomal dominant popliteal pterygium syndrome (PPS), also known as facio-genito-popliteal syndrome, is a rare congenital disorder characterized by a combination of orofacial, musculoskeletal, and genitourinary anomalies. It is caused by mutations in the IRF6 gene, the same gene implicated in Van der Woude syndrome, and is inherited in an autosomal dominant pattern with variable expressivity. PPS is allelic to Van der Woude syndrome but generally presents with a broader and more severe spectrum of features. The hallmark feature of popliteal pterygium syndrome is the presence of webbing (pter
How is Autosomal dominant popliteal pterygium syndrome inherited?
Autosomal dominant popliteal pterygium syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Autosomal dominant popliteal pterygium syndrome typically begin?
Typical onset of Autosomal dominant popliteal pterygium syndrome is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Autosomal dominant popliteal pterygium syndrome?
2 specialists and care centers treating Autosomal dominant popliteal pterygium syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.